Log in to your Inderes Free account to see all free content on this page.
Annexin Pharmaceuticals
0.461
SEK
-4.55 %
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
-4.55%
-10.66%
-13.02%
+18.51%
+88.41%
+71.88%
-28.32%
-40.05%
-85.92%
annexinpharma.com/investors
Annexin Pharmaceuticals is a biotechnology company with development in the Annexin A5 area. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for the treatment of patients with damage and inflammation in the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment and production of Annexin A5. The company was founded in 2014 and is based in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ANNX
Daily low / high price
0.45 / 0.495
SEK
Market cap
245.7M SEK
Turnover
201.96K SEK
Volume
428K
Financial calendar
Annual report
06.02.2025
Interim report
16.04.2025
General meeting
15.05.2025
Interim report
17.07.2025
Interim report
23.10.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Mikael Lönn | 26.0 % | 26.0 % |
| Arne Andersson | 10.9 % | 10.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Redeye: Annexin Q3 - Presented positive top-line data during the quarter
Annexin Pharmaceuticals AB: BioStock: Annexin: Could ANXV replace anti-VEGFs?
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio